Here’s what you should know:
1. Dr. Oberstein comes to NYU Langone from New York City-based Columbia University, where he was a member of the Herbert Irving Comprehensive Cancer Center and an assistant professor.
2. He has a prominent research background based in clinical trials. Specifically, Dr. Oberstein’s research is centered on the design and implementation of studies that take laboratory research and apply it to patients.
3. In addition to his research efforts, Dr. Oberstein will see patients and help expedite study progress at NYU Langone Health.
NYU Langone Health’s Perlmutter Cancer Center Director Benjamin Neel, MD, PhD, said, “In 2018 for the first time, GI cancers will cause more cancer deaths in the U.S. than any other organ system. Dr. Oberstein’s experience in designing clinical trials for these cancers and his expertise in bringing basic research findings to the patient’s bedside strengthen our already formidable GI cancer research team.”
More articles on gastroenterology:
9 recent ASC acquisitions & partnerships — January 2018
Arkansas Surgery & Endoscopy Center sold for $3.4 million — 5 insights
New York hospital weighing applying for grant to modernize ASC, other facilities — 3 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.